Keywords: sonus, refocuses, operations, ultrasound, contrast, agent, flounders
Sonus refocuses operations as ultrasound contrast agent flounders
Article | 17 October 2000
Sonus Pharmaceuticals has decided to pull the plug on itsfluorocarbon-based ultrasound contrast agent EchoGen (perflenapent injectable emulsion), after what chief ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
